Related Experiment Video
Updated: Aug 3, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
MUL1 gene polymorphisms and Parkinson's disease risk
Reyisha Taximaimaiti1,2, Hongyan Li1
1Neurology Department of the People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Acta Neurologica Scandinavica
|February 23, 2019
Summary
Genetic variants in the MUL1 gene, specifically the T allele at rs529974, are linked to an increased risk of Parkinson's disease (PD). This finding may aid in early PD diagnosis and personalized treatment strategies.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Parkinson's disease (PD) affects millions globally, with gene therapy offering potential cures.
- The MUL1 gene has been implicated in PD pathogenesis, but specific genetic variants remain unidentified.
Purpose of the Study:
- To investigate the association between MUL1 gene variants and Parkinson's disease risk in a Chinese population.
- To test the hypothesis that specific MUL1 gene variants contribute to PD susceptibility.
Main Methods:
- A case-control study involving 100 PD patients and 100 age- and gender-matched controls.
- Genotyping of ten single nucleotide polymorphisms (SNPs) in the MUL1 gene using Sanger sequencing.
Main Results:
- The rs529974 polymorphism in the MUL1 gene showed a significant association with PD risk.
- Carrying the T allele at rs529974 was associated with an increased tendency for PD (OR = 0.353, P = 0.003).
- This association was independent of patient gender, clinical characteristics, and PD symptom severity.
Conclusions:
- The T allele of rs529974 in the MUL1 gene is a potential susceptibility factor for Parkinson's disease.
- These findings could inform early PD diagnosis and personalized pharmacotherapy.
- Larger-scale studies are required for confirmation and further validation.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...